deltatrials
Unknown PHASE3 NCT00005663

A Study of Valacyclovir as Treatment for Genital Herpes Simplex Virus in HIV-Infected Patients

An International, Randomized, Double-Blind, Placebo-Controlled Study of Valacyclovir for the Suppression of Recurrent Ano-Genital HSV Infections in HIV-Infected Subjects

Sponsor: Glaxo Wellcome

Conditions HIV Infections Herpes Genitalis Herpes Simplex
Interventions Valacyclovir hydrochloride
Updated 5 times since 2017 Last updated: Jun 23, 2005 Started: Jun 30, 1999

Listed as NCT00005663, this PHASE3 trial focuses on HIV Infections and Herpes Genitalis and remains ongoing. Sponsored by Glaxo Wellcome, it has been updated 5 times since 1999, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE3

    Status: Unknown Status → Unknown

  3. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Unknown Status PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Unknown Status PHASE3

    First recorded

Jun 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Glaxo Wellcome
Data source: NIH AIDS Clinical Trials Information Service

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Altamonte Springs, United States, Berkeley, United States, Beverly Hills, United States, Charlotte, United States, Edmonton, Canada, Fort Lauderdale, United States, Hackensack, United States, Houston, United States, Indianapolis, United States, Los Angeles, United States and 14 more location s